Acute stroke takes approximately 2000 lives every year in Norway and is the third most common cause of death. Acute ischemic infarctions are the most common type of acute stroke and can be treated with intravenous thrombolytic therapy if the patients are brought to treatment within 4.5 hours. The treatment goal is to achieve restored blood flow to the ischemic brain tissue without causing a symptomatic intracerebral haemorrhage which is a side effect of the treatment. The aim of this study was to investigate the short-term effect and complications of intravenous thrombolysis, and to investigate whether or not the frequency of thrombolysis and “door-to- needle-time” were up to national quality standards in a thrombolysis treated population. We studied the medical records for the ischemic stroke population at Akershus University Hospital from January 2016 to December 2017. A total of 237 patients received intravenous thrombolysis and clinical information was retrospectively gathered from their records and from an internal quality-proofed register. Information for the National stroke registry was used to compare results to national standards. Our study revealed that 70% of the patients have a decrease in NIHSS-score within 24 to 36 hours of administering the intravenous thrombolysis. Five patients suffered a SICH, equal to 2% of the population, as a complication to the thrombolytic treatment. Of these patients one had a stroke mimic diagnosis. The frequency of thrombolysis at Akershus University hospital was at 16.6% and the median for door-to-needle-time was at 38 minutes in 2017. Both are within what is classified as high goal achievements in the National stroke registry report from 2017.